Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via GPCR modulation. SEP-631’s first-in-human data at the AAAAI meeting could ...
CytomX reports promising Phase 1 data for CX-2051 in advanced colorectal cancer, with planned Phase 2 study in 2026. CytomX Therapeutics announced positive interim results from its Phase 1 study of CX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results